2. Türk C., Petřík A., Sarica K., et al. EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. Eur Urol.2016;69(3):468–474. https://doi.org/10.1016/j.eururo.2015.07.040

3. William J. H. Epidemiology of kidney stones in the United States.Nutritional and Medical Management of Kidney Stones. Humana. Cham. 2019. С. 3–17. https://doi.org/10.1007/978-3-030-15534-6_1

4. Evan A.P. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr. Nephrol. 2010;25:5:831–841. https://doi.org/10.1007/s00467-009-1116-y

5. Россоловский А.Н., Березинец О.Л., Блюмберг Б.И. Мочекаменная болезнь: эволюция представлений (обзор). Бюллетень медицинских интернет-конференций. Общество с ограниченной ответственностью «Наука и инновации». 2014;4(1):84–86.

6. Trinchieri A. Epidemiology of urolithiasis: an update. Clinical cases in mineral and bone metabolism.2008;5:2:101–106. PMID: 22460989.

7. Romero V., Akpinar H., Assimos D.G. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2-3):e86–e96. PMID: 20811557.

8. Turney B.W., Reynard J.M., Noble J.G., Keoghane S.R. Trends in urological stone disease. BJU Int.2012;109(7):1082–1087. https://doi.org/10.1111/ j.1464-410X.2011.10495.x

9. Akoudad S., Szklo M., McAdams M.A., et al. Correlates of kidney stone disease differ by race in a multi-ethnic middle aged population: The ARIC Study. Prev Med. 2010;51(5):416–420. https://doi.org/10.1016/j.ypmed.2010.08.011

10. Wändell P., Carlsson A.C., Li X., et al. Urolithiasis in second‐generation immigrant children younger than 18 years of age in Sweden. Acta Paediatrica.2020. https://doi.org/10.1111/apa.15298

11. Alexander R.T., Hemmelgarn B.R., Wiebe N., et al. Kidney stones and cardiovascular events: a cohort study. Clinical Journal of the American Society of Nephrology. 2014;9:3:506–512. Doi: https://doi.org/10.2215/CJN.04960513

12. Aviram M. Atherosclerosis: cell biology and lipoproteins – paraoxonases protect against atherosclerosis and diabetes development. Curr Opin Lipidol. 2012;23(2):169–171. https://doi.org/10.1097/MOL.0b013e3283513594

13. Menon M., Resnick M.I. Urinary lithiasis: etiology, diagnosis, and medical management In: Campbell’s Urology, 8th Ed. WB Saunders Company: Philadelphia. PA. 2002. С. 3242–3305.

14. Gaharwar Y.S., Topale S.S., Farouqi U., Prakash B.S. Role of atherosclerosis in pathogenesis of renal stone disease: Do all roads lead to Rome?. J Mahatma Gandhi Inst Med Sci. 2017;22:4–7. https://doi.org/10.4103/0971-9903.202014

15. Skolarikos A., Straub M., Knoll T., et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015;67(4):750–763. https://doi.org/ 10.1016/j.eururo.2014.10.029

16. Lin S.K., Liu J.M., Chang Y.H., et al. Increased risk of endotracheal intubation and heart failure following acute myocardial infarction in patients with urolithiasis: a nationwide population-based study Ther Clin Risk Manag.2017;13:245–253. https://doi.org/10.2147/TCRM.S123702

17. Ernandez T., Bonny O. Kidney stone as a cardiovascular risk marker. Rev Med Suisse 2014;10(441):1656–1660. PMID: 25322624.

18. Kim S.Y., Song C.M., Bang W., et al. Nephrolithiasis predicts ischemic stroke: A longitudinal follow-up study using a national sample cohort. International journal of medical sciences.2019;16:8:1050–1056. https://doi.org/10.7150/ijms.34417

19. Mackness M.I., Durrington P.N., Ayub A., Mackness B. Low serum paraoxonase: a risk factor for atherosclerotic disease? Chem Biol Interact. 1999;14:119–120:389–397. https://doi. org/10.1016/s0009–2797 (99)00050–2

20. Lai C.H., Huang L.C., Holby S.N., et al. Kidney stone history and adverse outcomes after percutaneous coronary intervention.Urology.2020;136:75–81. https://doi.org/10.1016/j.urology.2019.10.009

21. Роюк Р.В., Яровой С.К., Гусева Н.А. и др. Эпидемиологические аспекты сочетания нефролитиаза и хронических заболеваний сердечно-сосудистой системы. Исследования и практика в медицине. 2020;7(1):38–47. https://doi.org/10.17709/2409-2231-2020-7-1-4

22. Жариков А.Ю., Брюханов В.М., Зверев Я.Ф., Лампатов В.В. Современные методы моделирования оксалатного нефролитиаза. Нефрология. 2008;12(4):28–35. https://doi.org/10.24884/1561-6274-2008-12-4-28-35

23. Муркамилов И.Т., Айтбаев К.А., Фомин В.В., Юсупов Ф.А., Счастливенко А.И. Инсульт у пациентов с мочекаменной болезнью: распространенность и факторы риска. The Scientific Heritage. 2020;47(2):40–44.

24. Rosa D., Villa G., Montanari E., et al. The relationship between urolithiasis, metabolic syndrome and nurse shift work. A literature review.International Journal of Urological Nursing.2020. https://doi.org/10.1111/ijun.12233

25. Тызьо Д.В., Ахназарян М.С., Макеева А.В. Сравнительная оценка факторов риска в патогенезе развития мочекаменной болезни почек. Научное обозрение. Педагогические науки.2019;5:115–119.

26. Lee Y.C., Huang S.P., Juan Y.S., Huang T.Y., Liu C.C. Impact of metabolic syndrome and its components on kidney stone in aging Taiwanese males. Aging Male. 2016;19(3):197-201. https://doi.org/10.1080/13685538.2016.1174987

27. Cho S.T., Jung S.I., Myung S.C., Kim T.H. Correlation of metabolic syndrome with urinary stone composition. Int J Urol. 2013;20: 208–213. https://doi.org/10.1111/j.1442-2042.2012.03131.x

28. Arafa A., Eshak E.S., Iso H. Oxalates, Urinary Stones and Risk of Cardiovascular Diseases. Medical Hypotheses. 2020.С. 109570. https://doi.org/10.1016/j.mehy.2020.109570

29. Domingos F., Serra A. Metabolic syndrome: a multifaceted risk factor for kidney stones. Scand J Urol. 2014;48(5):414–419. https://doi.org/10.3109/21681805.2014.903513

30. Лелявин К.Б., Селиверстова Т.Г., Рева А.А. Мочекаменная болезнь как новый компонент «метаболически здорового» ожирения. Современные проблемы науки и образования. 2019.4.URL: http://www.science-education.ru/ru/article/view?id=29075 (дата обращения: 17.05.2020).

31. Cupisti A., Meola M., D’Alessandro C., et al. Insulin resistance and low urinary citrate excretion in calcium stone formers. Biomed Pharmacother.2007;61(1):86–90. https://doi.org/10.1016/j.biopha.2006.09.012

32. Taylor E.N., Mount D.B., Forman J.P., Curhan G.C. Association of prevalent hypertension with 24-hour urinary excretion of calcium, citrate, and other factors. Am J Kidney Dis. 2006;47(5):780–789. https://doi.org/10.1053/j.ajkd.2006.01.024

33. Wrobel B.M., Wrobel B., Hormann M., Strohmaier W.L. Overweight and obesity: risk factors in calcium oxalate stone disease? Adv Urol.2012;2012:438707. https://doi.org/10.1155/2012/438707

34. Аляев Ю.Г., Кузьмичева Г.М., Руденко В.И. Современные аспекты цитратной терапии у больных мочекаменной болезнью. Врачебное сословие. 2004;4:20-24.

35. Медведев В.Л., Татевосян А.С., Дмитренко Г.Д., и др. Комбинированное лечение больного с коралловидным камнем почки. Клинический случай. Инновационная медицина Кубани. 2019;(1):36–43.

36. Geraghty R., Abdi A., Somani B., Cook P., Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ open. 2020;10:1. http://dx.doi.org/10.1136/bmjopen-2019-032094

37. Hernandez-Baixauli J., Quesada-Vázquez S., Mariné-Casadó R., et al. Detection of Early Disease Risk Factors Associated with Metabolic Syndrome: A New Era with the NMR Metabolomics Assessment.Nutrients. 2020;12:3:806. https://doi.org/10.3390/nu12030806

38. Ding Q., Ouyang J., Fan B., et al. Association between Dyslipidemia and Nephrolithiasis Risk in a Chinese Population. Urologia internationalis. 2019;103:2:156–165. https://doi.org/10.1159/000496208

39. Гаджиев Н.К., Малхасян В.А., Мазуренко Д.А. и др. Мочекаменная болезнь и метаболический синдром. Патофизиология камнеобразования. Экспериментальная и клиническая урология.2018;1:66–75. https://doi.org/10.29188/2222-8543-2018-9-1-66-75.

40. Kabeya Y., Kato K., Tomita M., et al. Associations of insulin resistance and glycemic control with the risk of kidney stones. Intern Med.2012;51:699–705. https://doi.org/10.2169/ internalmedicine.51.6426

41. Голованов С.А., Просянников М.Ю., Анохин Н.В., Сивков А.В., Аполихин О.И. Функциональное состояние клеточных мембран у больных мочекаменной болезнью. Экспериментальная и клиническая урология. 2019;2:87–91. https://doi.org/10.29188/2222-8543-2019-11-2-87-91

42. Yanagawa K., Takeda H., Egashira T., et al. Age-related changesin alpha-tocopherol dynamics with relation to lipid hydroperoxide content and fluidity of rat erythrocyte membrane. J Gerontol A Biol Sci Med Sci. 1999;54(9):B379-B783. https://doi.org/10.1093/gerona/54.9.B379

43. Kirejczyk J.K., Korzeniecka-Kozerska A., Baran M., et al. Dyslipidaemia in overweight children and adolescents is associated with an increased risk of kidney stones. Acta Paediatr.2015;104(9):e407–413. https://doi.org/10.1111/apa.13079

44. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16(1): 6–31. https://doi.org/10.26442/2075082X.2019.1.190179

45. Ljunnghall S., Hedstrand H. Renal stones and coronary heart disease. BMJ. 1976;4:5996. ID 580. https://doi.org/10.1136/bmj.4.5996.580-a

46. Robertson W.G., Peacock M., Baker M. et al. Studies on the prevalence and epidemiology of urinary stone disease in man in Leeds. Br. J. Urol. 1983;55:6:595–598. https://doi.org/10.1111/j.1464-410X.1983.tb03383.x

47. Shang W., Li Y., Ren Y., et al. Nephrolithiasis and risk of hypertension: a meta-analysis of observational studies. BMC nephrology.2017;18:1:344. https://doi.org/10.1186/s12882-017-0762-8

48. Батько А.Б. Патологические паттерны артериальной гипертензии и мочекаменной болезни. Эффективная фармакотерапия. 2019;15:29:12–15. https://doi.org/10.33978/2307-3586-2019-15-29-12-15

49. Asplin J.R., Mandel N.S., Coe F.L. Evidence of calcium phosphate super saturation in the loop of Henle. Am J Physiol.1996;270(4 Pt 2):F604-F613. https://doi.org/10.1152/ajprenal.1996.270.4.F604

50. Kum F., Wong K., Game D., et al. Hypertension and renal impairment in patients with cystinuria: findings from a specialist cystinuria centre.Urolithiasis. 2019;47:4:357–363. https://doi.org/10.1007/s00240-019-01110-8

51. Ferraro P.M., Bargagli M., Trinchieri A., Gambaro G. Risk of Kidney Stones: Influence of Dietary Factors, Dietary Patterns, and Vegetarian–Vegan Diets.Nutrients.2020;12:3:779. https://doi.org/10.3390/nu12030779

52. Rendina D., De Filippo G., D’Elia L., Strazzullo P. Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence. J Nephrol. 2014;27(4):371–376. https://doi.org/10.1007/ s40620-014-0085-9